Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Peñarrubia, J.
Right arrow Articles by Balasch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peñarrubia, J.
Right arrow Articles by Balasch, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 18, No. 12, 2689-2697, December 2003
© 2003 European Society of Human Reproduction and Embryology

LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH

Joana Peñarrubia1, Francisco Fábregues1, Montserrat Creus1, Dolors Manau1, Roser Casamitjana2, Marta Guimerá1, Francisco Carmona1, Juan A. Vanrell1 and Juan Balasch1,3

1 Institut Clinic of Gynecology, Obstetrics and Neonatology and 2 Hormonal Laboratory, Faculty of Medicine–University of Barcelona, Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

3 To whom correspondence should be addressed at: Institut Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic; C/Casanova 143, 08036 Barcelona, Spain. e-mail: jbalasch{at}medicina.ub.es

BACKGROUND: There has been much debate about the effect of ‘residual’ LH levels in normogonadotrophic women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH ovarian stimulation. The aim of this prospective study, where receiver-operating characteristic (ROC) analysis was used, was to assess further the usefulness of serum LH levels as predictors of ovarian response, assisted reproduction treatment outcome, and the outcome of pregnancy when measured throughout the ovarian stimulation period in a large cohort of such assisted reproduction treatment women. METHODS: A total of 246 consecutive women undergoing their first cycle of IVF or ICSI treatment were included in this study. Blood samples for hormone analyses were obtained on day S0 (the day when pituitary suppression was evidenced) and every other day from stimulation day 5 (S5) until the day of hCG injection. RESULTS: LH serum levels throughout ovarian stimulation treatment were similar for cancelled (n =32) versus non-cancelled (n = 214) cycles, non-conception (n = 132) versus conception (n = 82) cycles, and ongoing pregnancy (n = 66) versus early pregnancy loss (n = 16) groups. There was no correlation between LH serum levels in non-cancelled cycles and parameters of ovarian response and assisted reproduction treatment outcome. ROC analysis showed that serum LH concentration during ovarian stimulation was unable to discriminate between cancelled and non-cancelled cycles, conception versus non-conception cycles, or early pregnancy loss versus ongoing pregnancy groups. CONCLUSIONS: Serum LH measurements during ovarian stimulation with recombinant FSH under pituitary suppression in normogonadotrophic women undergoing assisted reproduction treatment cannot predict ovarian response, IVF/ICSI outcome, implantation, and the outcome of pregnancy. Thus, there is little underlying physiological support for the addition of LH in stimulation protocols if daily doses of an appropriate GnRH agonist (leuprolide or triptorelin having lower potency than buserelin) and a step-down regimen of recombinant FSH administration are used.

Key words: assisted reproduction/early pregnancy loss/recombinant FSH/LH/ovarian stimulation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
A. Weghofer and N. Gleicher
Ovarian function: a theory of relativity
Hum. Reprod., January 1, 2009; 24(1): 17 - 19.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
B.C.J.M. Fauser, K. Diedrich, P. Devroey, and on behalf of the Evian Annual Reproduction (EVAR)
Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation
Hum. Reprod. Update, January 1, 2008; 14(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. Safdarian, F. S. Mohammadi, A. Alleyassin, M. Aghahosseini, A. Meysamie, and E. Rahimi
Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916)
Hum. Reprod., September 1, 2007; 22(9): 2449 - 2454.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Balasch, F. Fabregues, J. Penarrubia, F. Carmona, R. Casamitjana, M. Creus, D. Manau, G. Casals, and J. A. Vanrell
Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH
Hum. Reprod., July 1, 2006; 21(7): 1884 - 1893.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
G. Griesinger, A. Schultze-Mosgau, K. Dafopoulos, A. Schroeder, A. Schroer, S. von Otte, D. Hornung, K. Diedrich, and R. Felberbaum
Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol
Hum. Reprod., May 1, 2005; 20(5): 1200 - 1206.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Penarrubia, F. Fabregues, D. Manau, M. Creus, G. Casals, R. Casamitjana, F. Carmona, J. A. Vanrell, and J. Balasch
Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment
Hum. Reprod., April 1, 2005; 20(4): 915 - 922.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Penarrubia, F. Fabregues, D. Manau, M. Creus, F. Carmona, R. Casamitjana, J. A. Vanrell, and J. Balasch
Previous cycle cancellation due to poor follicular development as a predictor of ovarian response in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment
Hum. Reprod., March 1, 2005; 20(3): 622 - 628.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
I. Cedrin-Durnerin, D. Grange-Dujardin, A. Laffy, I. Parneix, N. Massin, J. Galey, L. Theron, J.P. Wolf, C. Conord, P. Clement, et al.
Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study
Hum. Reprod., September 1, 2004; 19(9): 1979 - 1984.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.